N/A
N=17
Vagus Nerve Stimulation as Treatment for Long Covid
Long COVID · Chronic Fatigue Syndrome
Bottom Line
View on ClinicalTrials.gov: NCT05608629 ↗Enrolled (actual)
17
Serious AEs
0.0%
Results posted
Jan 2024
Primary outcome: Primary: Number of Participants With Treatment Success — 8 Participants
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Transcutaneous Non-Invasive Vagus Nerve Stimulation (Device)
- Age
- Pediatric, Adult, Older Adult
- Sex
- All
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Primary completion
- Dec 2022
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants With Treatment Success |
8 | — |
| SECONDARY Number of Participants With Change in the Profile of Mood States (POMS) |
5 | — |
Summary
Many patients do not recover following Covid infection. The resulting illness is called Long Covid. Because there is no agreed upon treatment for this ailment, the research team has decided to do an open label pilot study using non-invasive, transcutaneous stimulation of the auricular branch of the vagus nerve. Inclusion criteria required the patient to fulfill criteria for having chronic fatigue syndrome. To date, fourteen patients provided evaluable data. Eight of these fulfilled the study's requirements for treatment success.
Eligibility Criteria
Inclusion Criteria
- Patients had to have had COVID
- Patients have to fulfill the 1994 case definition for chronic fatigue syndrome.
Exclusion Criteria
- BMI > 30
Data sourced from ClinicalTrials.gov (NCT05608629). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.